Curexo Secures First Sales Contract in the US with American Investment Firm

[Asia Economy Reporter Hyunseok Yoo] Curexo, a medical robot specialist company, announced on the 3rd that its investment company, the U.S. corporation Think Surgical Inc., signed a sales contract for the artificial joint surgery robot ‘TSolution One’ with the largest hospital in New Jersey, USA, on the 2nd.

The product covered by this contract is a knee joint surgery robot that received FDA approval in the U.S. last October, marking the first sales contract within the United States. Hackensack University Medical Center is the largest hospital in New Jersey and ranked 2nd in the U.S. News & World Report 2019-20 Best Hospitals rankings. It is recognized as the top hospital for various high-risk surgeries, including orthopedics. It is also one of the five institutions participating in the clinical trials proving the efficacy and safety for the FDA approval of TSolution One.

Michael A. Kelly, the center director, said, “We are very pleased to be the first hospital to introduce a fully automated surgical robot equipped with innovative technology to treat knee osteoarthritis,” adding, “This reflects our hospital’s commitment to providing the best treatment to patients by utilizing advanced technology.”

John Hahn, CEO of Think Surgical, stated, “We are dedicated to improving the lives of patients suffering from severe osteoarthritis and advancing orthopedic technology,” and expressed the significance of the contract by saying, “We are honored to provide the TSolution system that will transform orthopedic surgery to patients through Hackensack University Medical Center.”

Curexo believes that the clinical effectiveness and usability of TSolution One’s knee joint surgery have already been proven through commercialization in Korea, and has long awaited sales activation in the U.S. market for global expansion. Curexo CEO Jaejun Lee said, “TSolution One, a fully automated (active) surgical robot, is receiving a good response in the U.S. market due to its unique advantages,” adding, “Other institutions participating in clinical trials, including Ohio, Texas, North Carolina, and New York, have also confirmed the product’s effectiveness, and we expect additional sales through this.” He continued, “We plan to quickly respond to product improvements reflecting feedback from the local market to secure market competitiveness.”

Meanwhile, Curexo developed its own surgical robot ‘CUVIS-joint’ by reflecting domestic user requirements for fully automated surgical robots and applied for domestic approval on the 17th.

Curexo CEO Jaejun Lee said, “In the rapidly changing surgical robot market, we judged that we cannot rely solely on the development capabilities of the investment company to preoccupy and survive,” adding, “Our goal is to cultivate our own development capabilities through the rapid commercialization of ‘CUVIS-joint,’ which reflects key domestic development requirements, and to create development and sales synergy with the investment company’s TSolution One.”

This content was produced with the assistance of AI translation services.